Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab + Chemotherapy as Neoadjuvant Therapy for HER2+ Gastric/GEJ Cancer
NCT07273981Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Xijing Hospital. Primary endpoint: Major pathological response rate at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zanidatamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07273981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273981.